ReviewFrontiers in pharmacology2021
Recent Advances in Pharmaceutical Cocrystals: From Bench to Market.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Systematic Scale-Up of Mechanochemical Paracetamol-Oxalic Acid Cocrystal Synthesis across Multiple Milling Technologies.Organic process research & development · 2026Article
- Green manufacturing of amoxicillin trihydrate: a malic acid-assisted crystallization framework enhanced by Taguchi-ANN optimization.RSC advances · 2026Article
- ML-Driven Pharmaceutical Cocrystal Technology: Advances in Screening, Property Prediction and Applications.AAPS PharmSciTech · 2026Review
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Enhancing the Solubility of Indomethacin: A Breakthrough with Cocrystal Formation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Conformational Landscape, Polymorphism, and Solid Forms Design of Bicalutamide: A Review.Molecules (Basel, Switzerland) · 2025Review
- Pharmaceutical Co-crystal of Ketoconazole-adipic Acid: Excipient Compatibility and In Silico Antifungal Potential Studies.Pharmaceutical research · 2025Article
- Understanding the Synthon Preferences in Molecular Ionic Cocrystals of Trimethoprim-An Experimental and Computational Study.ACS omega · 2025Article
- Reinforcing Restorative Dentistry: The Dual Role of Carbon Nanotubes in Material Enhancement and Therapy.International journal of dentistry · 2025Review
- Discovery of a Novel Co-crystal of Chrysin and Oroxylin A with Anticancer Properties from Leaves ofAnti-cancer agents in medicinal chemistry · 2025Article
- Current Perspectives on Development and Applications of Cocrystals in the Pharmaceutical and Medical Domain.Cureus · 2024Review
- Analysis of the Dissolution Behavior of Theophylline and Its Cocrystal Using ATR-FTIR Spectroscopic Imaging.Molecular pharmaceutics · 2024Article
- Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Frontiers in immunology · 2024Article
- Sugars and Polyols of Natural Origin as Carriers for Solubility and Dissolution Enhancement.Pharmaceutics · 2023Review
- Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems.Pharmaceutics · 2023Review
- New Lidocaine-Based Pharmaceutical Cocrystals: Preparation, Characterization, and Influence of the Racemic vs. Enantiopure Coformer on the Physico-Chemical Properties.Pharmaceutics · 2023Article
- Patent and Marketing Exclusivities 101 for Drug Developers.Recent patents on biotechnology · 2023Review
- New Solid Forms of Nitrofurantoin and 4-Aminopyridine Salt: Influence of Salt Hydration Level on Crystal Packing and Physicochemical Properties.Molecules (Basel, Switzerland) · 2022Article
- Simultaneous Improvement of Dissolution Behavior and Oral Bioavailability of Antifungal Miconazole via Cocrystal and Salt Formation.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics profile of active pharmaceutical ingredients (APIs) in the solid pharmaceutical dosage forms is largely dependent on the solid-state characteristics of the chemicals to understand the physicochemical properties by particle size, size distribution, surface area, solubility, stability, porosity, thermal properties, etc. The formation of salts, solvates, and polymorphs are the conventional strategies for altering the solid characteristics of pharmaceutical compounds, but they have their own limitations. Cocrystallization approach was established as an alternative method for tuning the solubility, permeability, and processability of APIs by introducing another compatible molecule/s into the crystal structure without affecting its therapeutic efficacy to successfully develop the formulation with the desired pharmacokinetic profile. In the present review, we have grossly focused on cocrystallization, particularly at different stages of development, from design to production. Furthermore, we have also discussed regulatory guidelines for pharmaceutical industries and challenges associated with the design, development and production of pharmaceutical cocrystals with commercially available cocrystal-based products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.